ESR1 and breast cancer: Of 3284 ER+ve/HER2−ve breast cancers with results for the Oncotype-trained risk classification, 48.9% were classified low risk (DMFS10 = 87.9%), 35.8% intermediate risk (DMFS10 = 78.6%) and 15.3% high risk (DMFS10 = 67.5%) (Table 2; Figs. 1a, 2).